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1--D-Arabinofuranosylcytosine (Ara-C) is a potent
antineoplastic drug used in the treatment of acute leu-
kemia. Previous biochemical studies indicated the in-
corporation of Ara-C into DNA reduced the catalytic
activity of human topoisomerase I by decreasing the
rate of single DNA strand religation by the enzyme by
2–3-fold. We present the 3.1 Å crystal structure of hu-
man topoisomerase I in covalent complex with an oli-
gonucleotide containing Ara-C at the 1 position of the
non-scissile DNA strand. The structure reveals that a
hydrogen bond formed between the 2-hydroxyl of
Ara-C and the O4 of the adjacent 1 base 5 to the
damage site stabilizes a C3-endo pucker in the Ara-C
arabinose ring. The structural distortions at the site of
damage are translated across the DNA double helix to
the active site of human topoisomerase I. The free
sulfhydryl at the 5-end of the nicked DNA strand in
this trapped covalent complex is shifted out of align-
ment with the 3-phosphotyrosine linkage at the cata-
lytic tyrosine 723 residue, producing a geometry not
optimal for religation. The subtle structural changes
caused by the presence of Ara-C in the DNA duplex
may contribute to the cytotoxicity of this leukemia
drug by prolonging the lifetime of the covalent human
topoisomerase I-DNA complex.
Human topoisomerase I solves the DNA topological problems
that arise from a wide variety of nuclear processes including
replication, transcription, and recombination (1, 2). The en-
zyme nicks one strand of duplex DNA using a transesterifica-
tion reaction that produces a transient 3-phosphotyrosine
linkage and guides the relaxation of either positive or negative
superhelical tension by a proposed “controlled rotation” mech-
anism (3). The enzyme then catalyzes a second transesterifica-
tion in which the free hydroxyl at the 5-end of the nicked DNA
strand attacks the phosphotyrosine bond, resealing the nick,
and releasing a more relaxed DNA molecule. Topoisomerase I
plays a vital role in maintaining DNA stability and is known to
travel with active replication and transcription complexes in
human cells (4, 5).
Human topoisomerase I is the sole target of the camptothe-
cins (CPT), a potent class of anticancer drugs used to treat
late-term solid malignancies (3, 4, 6). Camptothecin effectively
targets the religation phase of topoisomerase I catalysis by
stabilizing the covalent protein-DNA complex and trapping the
enzyme on DNA (7, 8). In this way, CPT converts topoisomer-
ase I into a cellular poison. Human topoisomerase I is also
affected by several forms of DNA damage, including abasic
lesions, wobble base pairs, and base pair mismatches (9–13).
Such lesions can impact each stage of topoisomerase I’s cata-
lytic cycle, including DNA binding, single-strand DNA cleav-
age, and religation.
1--D-Arabinofuranosylcytosine (Ara-C)1 is a nucleoside an-
alogue used in the treatment of acute leukemia (14, 15). Ara-C
and the standard cytosine DNA base differ by the presence of a
2-hydroxyl on the arabinose ring of the drug (Fig. 1). Ara-C is
thought to inhibit DNA polymerases central to replication and
repair processes, and thus to slow the growth of malignant cells
(16, 17). The detailed impact of Ara-C on human cells, however,
is poorly understood. Incorporation of Ara-C into DNA causes
localized alterations in the DNA duplex, including changes in
sugar pucker, base stacking, and backbone torsion angles (17,
18). Biochemical studies using human topoisomerase I have
revealed that Ara-C incorporation at the 1 position of the
intact (non-scissile) strand adjacent to the site of single-
strand DNA cleavage induces a 4–6-fold increase in covalent
topoisomerase I-DNA complexes caused by a 2–3-fold de-
crease in the rate of religation by the enzyme (12). Because
the stabilization of covalent topoisomerase I-DNA complexes
converts the enzyme into a cellular poison, the cytotoxicity of
Ara-C may be enhanced by this ability to impact the action of
topoisomerase I.
Human topoisomerase I is 765 amino acids (91 kDa) and is
composed of four domains: N-terminal (residues 1–200), core
(201–635), linker (636–712), and C-terminal domain (713–
765). Several crystal structures of human topoisomerase I DNA
complexes have been determined (3, 8, 13, 19–21). Core sub-
domains I and II form the “CAP” of human topoisomerase I that
contacts one side of the DNA, while core subdomain III, the
“CAT,” and the C-terminal domain contact the opposite side of
the DNA. The CAP and CAT regions of the enzyme together
wrap completely around the DNA duplex and position the
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active site residues within hydrogen bonding distance of the
scissile DNA phosphate group. Four of five active site residues,
Arg-488, Lys-532, Arg-590, and His-632, are located in core
subdomain III, while the catalytic Tyr-723 resides in the C-
terminal domain (3, 19, 20).
Structures of covalent human topoisomerase I-DNA com-
plexes containing an intact 3-phosphotyrosine linkage have
also been reported (8, 19). In these trapped covalent protein-
DNA complexes, the scissile phosphate contained a bridging
phosphorothiolate linkage, which, upon cleavage by topo-
isomerase I, generates a free 5-sulfhydryl unable to partici-
pate in strand religation (8, 19, 22). The use of 5-bridging
phosphorothiolate linkages to trap covalent complexes has
been successfully employed to examine several enzymes that
form transient 3-phosphotyrosine linkages, including eu-
karyotic type IB topoisomerases, viral topoisomerases, and
bacterial and phage tyrosine recombinases and integrases (8,
19, 22–28). Detailed biochemical studies have shown that the
presence of a 5-bridging phosphorothiolate linkage has a
marginal effect on the rate of cleavage by such enzymes
(down 2-fold), but lowers the rate of religation by at least
10,000-fold (24). In addition, x-ray crystallographic studies
have revealed that when the active form of human topo-
isomerase I (with the Tyr-723 residue intact) is used for
crystallization, a bridging phosphorothiolate linkage is re-
quired to obtain crystals (8, 19).
We determined the 3.1 Å crystal structure of a human topo-
isomerase I in covalent complex with a 22-base pair oligonu-
cleotide containing Ara-C at the 1 position of the non-scissile
DNA strand to elucidate the structural impact of Ara-C on this
enzyme. This is only the third structure of a covalent topo-
isomerase I-DNA complex reported to date (8, 19). We find that
Ara-C introduces numerous subtle structural changes, includ-
ing changes in sugar pucker and base position, that contribute
to a new positioning of the free 5-sulfhydryl away from the
3-phosphotyrosine linkage. Thus, the single-strand religation
reaction catalyzed by the enzyme is decreased, producing a
longer lived covalent protein-DNA complex.
MATERIALS AND METHODS
Protein Purification and DNA Oligonucleotides—The core domain of
human topoisomerase I (58 kDa, residues 175–659 including a nuclear
localization signal) was expressed using baculovirus in Spodoptera fru-
giperda (Sf9) insect cells as described (29). The 6.3-kDa C-terminal
domain of human topoisomerase I (residues 713–765) was expressed as
a GST fusion protein in Escherichia coli and immobilized on glutathione
S-Sepharose beads (Amersham Biosciences). Nuclear extracts of Sf9
cells expressing the 58 kDa core domain were mixed in batch with the
glutathione beads containing immobilized C-terminal domain, produc-
ing a reconstituted topoisomerase I complex. This complex was then
purified to homogeneity as described (29).
HPLC-purified DNA oligonucleotides were purchased from Oligos
Etc (Midlands, TX) and annealed as described. The following 22-bp
DNA duplex was created,
where ^ corresponds to the site of cleavage and the bold, underlined C
indicates the position of the Ara-C base. The G base in italics contained
a bridging phosphorothiolate linkage, which upon cleavage by human
topoisomerase I generates a free 5-sulfhydryl rather than a hydroxyl
(22–28). This method of trapping human topoisomerase I in covalent
complexes with duplex DNA has been used previously in structural
studies of this enzyme (8, 19), as well as in several detailed mechanistic
and biological studies of topoisomerases and related tyrosine recombi-
nases (22–28). Note that the Ara-C nucleotide is in the intact DNA
strand, and the G nucleotide containing the 5-bridging phosphorothio-
late linkage is in the scissile DNA strand.
Crystallization and Data Collection—Crystals of reconstituted hu-
man topoisomerase I in covalent complex with the 22-bp DNA duplex
containing an Ara-C site of damage at the intact 1 position were
grown by sitting drop vapor diffusion and cryoprotected as described
(19). Crystals belong to space group P32. Data were collected at
Brookhaven National Laboratory, beamline X12B, using x-ray radia-
tion of 1.1 Å wavelength, and a MAR CCD detector. Data were pro-
cessed, scaled, and reduced using HKL2000 (30).
Structure Determination and Refinement—The structure was deter-
mined by molecular replacement with AMoRe (31) using the crystal
structure of the human topoisomerase I reconstituted covalent complex
as a search model (PDB code 1A31; Ref. 19). 10% of the diffraction data
were set aside for the Rfree statistic prior to any structural refinement.
Partial hemihedral twinning was detected, with a twinning fraction of
8.8% and a twinning operation of (h, hk, l). The data were de-
twinned readily using the method of Yeates (32) as implemented in
CNS. The model was refined by rigid body, positional, thermal displace-
ment parameter, and simulated annealing methods in CNS using tor-
sion angle dynamics and the maximum likelihood function target.
Model rebuilding and manual adjustments into the electron density
maps were performed using the program O (33). Final refinement
included an overall B-factor, bulk solvent correction, and 33 well-or-
dered water molecules. The final structure yielded no Ramachandran
outliers as calculated by PROCHECK (34). Molecular graphics figures
were created with Molscript, Raster3D, DINO, and Povray (35–37).2
Coordinates have been deposited with the RCSB and assigned code
1NH3.
RESULTS
Overall Structure—The crystal structure of reconstituted hu-
man topoisomerase I in covalent complex with a 22-base pair
oligonucleotide containing Ara-C at the 1 position of the
non-scissile strand was determined to 3.1 Å resolution and
refined to crystallographic R and Rfree values of 0.24 and 0.31,
respectively (Table I). Human topoisomerase I-DNA complex
crystals are notoriously difficult to handle (3, 13, 19–21). In-
deed, in this case crystal fragility allowed the collection of
2 DINO: Visualizing Structural Biology (2002) www.dino3d.org.
SEQUENCE 1
FIG. 1. Chemical structures of Ara-C and ribocytosine nucleosides, with the O2, O3, and O5 oxygens labeled in each.
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diffraction data with only 70% completeness overall to 3.1 Å
resolution. In addition, because the trigonal space group P32
supports the possibility of hemihedral twinning, we examined
our data and found that twinning was present. A twinning
fraction of 0.088 and twinning operation of (h, hk, l) were
identified and used in refinement as implemented in CNS.
Despite these challenges, the final refined model includes all 22
base pairs of the DNA duplex, amino acid residues 203–626 of
the core domain of human topoisomerase I, and residues 719–
765 of the C-terminal domain.
The overall structure of this complex (the Ara-C structure) is
similar to the previously reported reconstituted human topo-
isomerase I enzyme in covalent complex with a non-damaged
DNA duplex (PDB code 1A31; Ref. 19; Fig. 2). The quality of the
electron density is good given the limited resolution and com-
pleteness of the diffraction data (Fig. 3). The CAP region of the
enzyme’s core domain (residues 203–432) sits above the DNA
and projects two -helices out along the DNA helical axis, while
the CAT (residues 433–635, 719–765) sits below the DNA and
assembles the active site around the scissile DNA phosphate.
Together, the CAP and CAT wrap completely around the DNA
duplex. The C-terminal domain is packed between the CAT and
the DNA and contains the fifth active site residue, the nucleo-
philic Tyr-723. The linker domain (residues 636–712) has been
observed in previous crystal structures to extend from the CAT
and C-terminal domains in the direction of the downstream
region of the DNA (3, 8, 20). This domain is not present in the
reconstituted protein construct used for these studies; the re-
constituted complex is composed of the human topoisomerase
I’s core domain (residues 175–659) and C-terminal domain
(713–765). The root mean square deviation (r.m.s.d.) between
the Ara-C structure and 1A31 is 0.89 Å over all protein atoms
(Table II). Shifts in position of up to 2.6 Å between individual
protein residues (e.g. Ala-326 in the CAP region) were observed
when the Ara-C and 1A31 structures are compared. Such shifts
are within the range observed when the protein regions of other
human topoisomerase I DNA complexes are compared (13,
20, 21).
The DNA duplex in the Ara-C structure is similar in overall
structure to that observed in 1A31 (Fig. 2). In addition, like all
previously described topoisomerase I-DNA complexes, the DNA
molecules pack head-to-tail in a pseudocontinuous helix. The
r.m.s.d. over all nucleic acid atoms between the two structures
is 1.2 Å (Table II). The ends of the DNA duplex shift in position
by up to 5.4 Å (Fig. 2); similar shifts in position of the ends of
the DNA duplexes have been observed in previous human
topoisomerase I structures (13, 20, 21).
Impact of Ara-C on DNA Base Pairing—An Ara-C:G base
pair at the 1 intact: scissile position in the Ara-C structure
replaces the A:T base pair at this position in 1A31, a previous
covalent human topoisomerase I DNA complex (19). The pres-
FIG. 2. Crystal structure of human topoisomerase I in covalent
complex with 22 base pair duplex DNA containing Ara-C at the
1 position of the non-scissile strand. The CAP region is composed
of core subdomains I (red) and II (green), and the CAT region is com-
posed of core subdomain III (blue) and the C-terminal domain (cyan).
The 10 and 12 positions in the DNA duplex (yellow) are labeled and
the Ara-C:G base pair at the 1 position of the Ara-C complex DNA
oligonucleotide is indicated in magenta. Superimposed in gray is the
structure of human topoisomerase I in covalent complex with a non-
damaged DNA oligonucleotide reported previously (19). Shifts in posi-
tion in the bases at the ends of the DNA duplex are indicated.
TABLE I
Crystallographic analysis of human topoisomerase I-Ara-C complex
Resolution (Å) (highest shell) 100  3.1 (3.2–3.1)
Space group P32
Unit cell dimensions ab73.0, c186.3, b90°, 120°
No. of total reflections 169,504
No. of unique reflections 13,878
Mean redundancy 12.2
Rsym
a (%) (highest shell) 13.5 (41.5)
Completeness (%) (highest shell) 69.3 (54.7)





Twin operator h, -h-k, -l
Twin fraction 0.088
r.m.s.d.
Bond length (Å) 0.0118
Bond angles (°) 1.55
Dihedral angles (°) 23.1
Improper angles (°) 1.59
Number of protein atoms 3825
Mean B value, protein atoms (Å2) 61.2
Number of DNA atoms 877
Mean B value, DNA atoms (Å2) 52.4
Number of solvent atoms 33
Mean B value, solvent atoms (Å2) 44.2
a Rsym  II/I, where I is the observed intensity and I is the average intensity of multiple symmetry-related observations of that reflection.
b Rcryst  FobsFcalc/Fobx, where Fobs and Fcalc are the observed and calculated structure factors.
c Rfree  FobsFcalc/Fobs for 10% of the data not used at any stage of structural refinement.
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ence of the Ara-C base causes subtle changes in the DNA
duplex that are localized largely at the 1 base pair (Fig. 4A).
The Ara-C and G bases shift by 1.4 and 0.75 Å, respectively,
from the positions of the A and T bases in the 1A31 structure.
The arabinose ring of the Ara-C nucleotide and the ribose ring
of the G nucleotide shift in position by up to 3.7 and 1.7 Å,
respectively, relative to the positions of the ribose rings in
1A31. The DNA bases surrounding the 1 base pair remain
relatively fixed in position, however, particularly in the scissile
strand and the upstream region of the intact strand (Fig. 4A).
The 2-hydroxyl of the Ara-C arabinose sugar ring extends in
the opposite direction from the equivalent group in a standard
ribose sugar (Fig. 1). The Ara-C arabinose ring exhibits a
C3-endo pucker, as predicted based on thermodynamic/ener-
getic considerations (Ref. 39; Fig. 4A). The deoxyribose ring of
the 1 adenine base in the intact strand of 1A31, in contrast,
exhibits the C2-endo pucker typical of B-form DNA bases. The
C3-endo pucker in the Ara-C arabinose ring is stabilized by a
2.5 Å intrastrand hydrogen bond between the Ara-C 2-hy-
droxyl and the O4 of the 1 adenine (Fig. 4B). Thus, the Ara-C
base exhibits a distinct sugar pucker that alters the 1 base
pair of the DNA duplex in the Ara-C structure. This change
impacts the position of the 5-end of the cleaved DNA strand
(see below), which helps to explain the decrease in the rate of
religation by human topoisomerase I observed with this form of
DNA lesion (12).
Two structures of DNA duplexes containing an Ara-C lesion
have been reported, one solution structure by nuclear magnetic
resonance spectroscopy (NMR) and one crystal structure (17,
18). While the atomic coordinates of the crystal structure are
not available, we compared the DNA duplex from our Ara-C
complex to the 12-base pair DNA duplex containing Ara-C
determined by NMR (Fig. 5). The r.m.s.d. over all 12 equivalent
base pairs between these two duplexes is 2.3 Å. The DNA bases
superimpose well, while the backbone is more deviant between
the two structures. The ribose at the 2 scissile position in the
Ara-C complex shifts in position by 0.7 Å from the equivalent
ribose in the NMR structure; this base is at the terminus of the
NMR duplex, however. The ribose ring of the 1 scissile strand
in the Ara-C structure shifts by 2.6 Å relative to the equivalent
ribose in the NMR structure, a change likely caused by the
break in the DNA backbone at this position. The arabinose
sugar of the Ara-C base shifts in position by 0.9 Å. While both
rings exhibit a C3-endo pucker, it is more extreme in the
topoisomerase I complex. Intrastrand hydrogen bonds between
the Ara-C 2-OH and the ribose O4 of the adjacent DNA base
are also formed in both structures. Thus, it appears that the
nick in the DNA backbone of the Ara-C topoisomerase I cova-
lent DNA complex stabilizes the C3-endo pucker in the Ara-C
arabinose sugar ring.
Active Site—The active site in the Ara-C structure is similar
overall to those observed in human topoisomerase I-DNA crys-
tal structures elucidated previously (3, 13, 19–21). Arg-488,
Lys-532, Arg-590, and Tyr-723 share an overall r.m.s.d. of 0.6 Å
with the equivalent residues in 1A31 (Fig. 6). His-632 is not
ordered in this structure, similar to the structure of a reconsti-
tuted covalent human topoisomerase I complex reported previ-
ously (19). The free 5-sulfhydryl group exhibits the largest
structural change at the active site, shifting in position by 2.6
Å relative to the 1A31 structure. Thus, in the Ara-C complex,
the 5-sulfhydryl is 3.7 Å from the 3-phosphotyrosine linkage,
while in the 1A31 structure, the equivalent group is only 2.5 Å
from the 3-phosphotyrosine linkage. Indeed, a rotation of the
5-sulfhydryl by 120 degrees in 1A31 places it in an ideal
position to perform an in-line attack on the covalent phosphate-
tyrosine bond. In the Ara-C complex, a similar alignment can-
not be formed without more significant structural changes.
This observation helps to explain the decreased rate of religa-
tion by human topoisomerase I using DNA substrates contain-
ing an Ara-C lesion at the intact 1 position (12).
The shift in the position of the free 5-end of the nicked DNA
strand in the Ara-C complex appears to be caused by the subtle
alteration in the 1 DNA base mediated by the arabinose
Ara-C sugar. The new position of the free 5-sulfhydryl in the
Ara-C complex brings it within 3.5 Å of the side chain of
Asn-722, the amino acid immediately N-terminal in sequence
to the catalytic Tyr-723. Asn-722 shifts in position by 0.5 Å
relative to the 1A31 structure; indeed, in the 1A31 complex,
Asn-722 is 4.5 Å from the free 5-sulfhydryl (19). The proximity
FIG. 3. Stereoview of electron density (2Fobs  Fcalc) for residues 396–401 of the human topoisomerase I Ara-C complex at 3.1 Å
resolution (contoured at 1).
TABLE II
RMSD between the human topoisomerase I Ara-C-containing DNA
complex and the covalent topoisomerase I-DNA complex reported
previously (1A31)
Residues or number of atoms r.m.s.d.
Å
All protein atoms 215–765 0.89
All C atoms 215–765 0.91
CAP protein atoms 215–434 0.86
CAT protein atoms 435–626 0.81
C-term protein atoms 720–765 0.82
All DNA atoms 877 1.21
P positions 44 1.29
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of the Asn-722 side chain to the free 5-end of the nicked DNA
strand in the Ara-C complex indicates that a hydrogen bond is
possible between these two groups. Asn-722 is conserved in all
known sequences of eukaryotic topoisomerases I and has been
implicated in the catalytic action of the enzyme. For example,
mutations of this residue in both human and Saccharomyces
cerevisiae topoisomerase I impact the enzyme’s sensitivity to
CPT and phases of its catalytic cycle (40).
DISCUSSION
The leukemia drug Ara-C contains a arabinose sugar ring
rather than the ribose standard to DNA and RNA bases. As
such, its 2-hydroxyl group is oriented in a manner distinct
from the equivalent RNA cytosine base (Fig. 1). Ara-C is
thought to elicit its antineoplastic effects by acting as a com-
petitive inhibitor of DNA polymerases  and  (12, 17, 41).
Even at low concentrations, however, the drug becomes incor-
porated into DNA and disrupts DNA metabolism (12, 17, 41).
Pourquier et al. (12) have shown that the presence of an Ara-C
base at the 1 position of the intact strand (opposite the site of
single-strand cleavage) slows the rate of DNA strand religation
by human topoisomerase I 2–3-fold (12). The extended lifetime
of the covalent topoisomerase I-DNA complex may contribute
to antineoplastic effects of Ara-C by enhancing chromosomal
instability. Indeed, human leukemia cells that lack detectable
levels of topoisomerase I are resistant to the effects of Ara-C
(12).
We determined the 3.1 Å resolution crystal structure of hu-
man topoisomerase I in covalent complex with a 22-base pair
DNA duplex containing Ara-C at the 1 position of the intact
strand (Fig. 2). The structure reveals that the Ara-C non-
standard 2-hydroxyl introduces numerous subtle structural
changes, particularly the 1 base pair (Fig. 4A). The 2-hy-
droxyl of Ara-C forms a hydrogen bond with the O4 of the 1
sugar, which stabilizes the C3-endo pucker exhibited by the
arabinose ring of Ara-C (Fig. 4B). These structural changes
cause the 1 base pair of the duplex to shift in position relative
FIG. 4. A, stereoview of a superposition of the central DNA bases from the Ara-C complex and a human topoisomerase I covalent complex with
non-damaged DNA (orange; Ref. 19). Each DNA base and its position within the 22-base pair duplex are indicated, as well as shifts in position in
DNA atoms at and around the site of damage. B, 2.5 Å intrastrand hydrogen bond between the 2-hydroxyl of Ara-C and the O4 of the 1 A base,
which stabilizes the C3-endo pucker of the Ara-C arabinose ring.
FIG. 5. Superposition of the DNA bases from the Ara-C com-
plex with a structure of a DNA duplex containing Ara-C deter-
mined by NMR (purple; Ref. 17). Each DNA base and its position
within its duplex are indicated, as well as shifts in position in DNA
atoms at and around the site of damage.
FIG. 6. Active site of the Ara-C complex superimposed on that
of the covalent human topoisomerase I complex with non-dam-
aged DNA (orange; Ref. 19). All the active site residues except His-
632 were visualized in both structures. The free 5-sulfhydryl group in
the Ara-C complex has shifted 2.6 Å relative to the previous structure
and is now positioned within 3.5 Å of the side chain of Asn-722.
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to the equivalent base pair in a covalent topoisomerase I DNA
complex without a site of damage reported previously (1A31;
Ref. 19). This, in turn, appears to cause the free 5-sulfhydryl
(which replaces the 5-hydroxyl in this trapped covalent com-
plex; 8, 19, 23–28) in the nicked DNA strand to shift away from
the covalent phosphotyrosine linkage and form a hydrogen
bond with the side chain of Asn-722, an interaction not ob-
served in previous topoisomerase I covalent complexes (Figs.
4A and 6). Taken together, these results indicate that the
subtle change of the duplex opposite the single-strand DNA
break shifts the free 5-end of the nicked strand away from the
covalent 3-phosphotyrosine linkage. These results likely
explain the impact on topoisomerase I activity reported by
Pourquier et al. (12).
This Ara-C structure provides additional insight into the
catalytic mechanism of human topoisomerase I. As the active
site residues are brought into place upon DNA binding, Asn-
722 does not appear to contact the DNA, as observed in several
non-covalent topoisomerase I DNA complexes (3, 13, 20, 21).
However, as the downstream region of DNA undergoes relax-
ation by the proposed controlled rotation mechanism, Asn-722
may have ample opportunity to hydrogen bond with the free
5-hydroxyl of the nicked strand. Indeed, after relaxation slows,
Asn-722 may play a crucial role via hydrogen bonding in guid-
ing the 5-hydroxyl into place for the religation phase of catal-
ysis. This interaction is likely to be transitory in reactions
involving non-damaged DNA. The change caused by the Ara-C
base appears to stabilize this interaction, allowing us to visu-
alize it in the structure presented here.
The importance of Asn-722 in human topoisomerase I and
the equivalent Asn-726 in S. cerevisiae topoisomerase I in the
catalytic cycle and camptothecin sensitivity of the enzyme
have been established by several careful biochemical studies.
For example, mutation of Asn-722 to histidine in human
topoisomerase I increases the rate of DNA cleavage, while
mutation to aspartic acid decreases the DNA binding affinity
of the enzyme (38). An N722S mutation in human topo-
isomerase I, in contrast, does not impact the catalytic activity
of the enzyme but does reduce its sensitivity to camptothecin
(40). We provide structural evidence in this and previous
work that sites of DNA damage impact the ability of Asn-722
to align the active site of human topoisomerase I both before
and after single-strand DNA cleavage by the enzyme (13).
This residue may play a similar role with other DNA lesions
that impact human topoisomerase I, including ethenoadenine
adducts, wobble base pairs, and uracil mismatches. In sum-
mary, we show that relatively subtle modifications caused by
the presence of a single 2-hydroxyl group on the opposite
side of the substrate DNA duplex can alter the structure of
the human topoisomerase I active site and impact the cata-
lytic action of the enzyme.
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